Final Results of ERBIMOX: A Randomized Phase II Study of Modified FOLFOX7 With or Without Cetuximab as First-Line Treatment for KRAS Wild-type Metastatic Colorectal Cancer.

10. Oktober 2025

Potthoff K, Marschner N, Müller L, Sahm S, Lerchenmüller C, Depenbusch R, Boller E, Niemeier B, Zirrgiebel U, Tesch H.

J Gastrointest Cancer. 2025 Jun 27;56(1):141. doi: 10.1007/s12029-025-01260-6.